Document is current
Any future updates will be listed below
-
Authors
Sahinovic, Ayshe https://orcid.org/0000-0003-0717-2342
Lau, Namson S.
Sabag, Angelo
Gordon, Rebecca
Cox, Amanda J.
Walker, Katie
Irwin, Christopher
Desbrow, Ben
Johnson, Nathan
Austin, Paul J.
Haber, Paul
McGregor, Iain S.
McCartney, Danielle https://orcid.org/0000-0002-7783-5220
-
Funding
Funding for this research was provided by:
The Lambert Initiative for Cannabinoid Therapeutics
- License Information
-
More Information
Article History
Received: 30 March 2025
Accepted: 13 July 2025
First Online: 21 August 2025
Declarations
:
: This study was approved by the Sydney Local Health District’s Human Research Ethics Committee (2021/ ETH11945; X21-0392), registered prospectively with the Australia and New Zealand Clinical Trials Registry (ACTRN12622000717752) on 19th May, 2022 and conducted in accordance with the standards of ethics outlined in the Declaration of Helsinki. All participants provided written informed consent prior to enrolment.
: Not applicable.
: A.S., R.G., K.W., I.S.M., and D.M. receive salary support from the Lambert Initiative for Cannabinoid Therapeutics. I.S.M. and D.M. has received consulting fees from Medicinal Cannabis Industry Australia (MCIA). I.S.M. has also received consulting fees Kinoxis Therapeutics and Janssen. I.S.M. and D.M. have served as expert witnesses in medicolegal cases involving cannabis and cannabinoids. I.S.M is also named as an inventor on several patents relating to novel cannabinoid therapeutics (PCT/AU2018/05089 and PCT/AU2019/050554).
